RT Journal Article
SR Electronic
T1 The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
JF International Society of Hair Restoration Surgery
FD Publication of the International Society of Hair Restoration Surgery
SP 153
OP 166
DO 10.33589/32.5.153
VO 32
IS 5
A1 Sukhmani Pannu
A1 Nathalie Ly
A1 Zehara Abidi
A1 Sophia Fruechte
A1 Ronda Farah
A1 Suleima Arruda
A1 Neil Sadick
A1 Maria Hordinsky
YR 2022
UL http://www.ISHRS-HTForum.org/content/32/5/153.abstract
AB Alopecia areata (AA), with a disease incidence of 2% in the USA, is the most common immune-mediated cause of hair loss in the world. There were no FDA approved treatments for AA in the past. All treatment modalities used alone or in combination with each other, were prescribed off label. The JAK inhibitor baricitinib was approved by the FDA in June 2022. While it’s a significant leap forward, we are still missing the safety profile data in multiple areas. Topical JAK inhibitors are being tested along with sublingual options including tofacitinib, ruxolitinib, and ritlecitinib. In this review, we discuss the JAK inhibitor baricitinib in detail, along with its dosing regimen, challenges presented in the clinic, missing data, and what the future may hold.